







Microfluidic Systems For Drug Analytical Applications

Dóra Bereczki

ELKH Centre for Energy Research Institute of Technical Physics and Materials Science Microsystems Laboratory

E-mail:bereczki.dora@ek-cer.hu

www.ek-cer.hu | www.mems.hu | www.biomems.hu


Introduction


Leading cause of death worldwide

- 19 million newly diagnosed cancer patients
- ~10 million cancer related deaths worldwide

Chemotherapy (CT) treatments

- 60%-of all cancer patients ~ I I million people
- Still low 5-years survival rate










MEMS

Results

- Create a tool with significantly reduced sample volumes and appropriate sensitivity.
- Microfluidic structures were designed by Clewin software and the chip was fabricated by soft lithography.
- Geometric parameters were optimized by modifying the chamber diamter and chamber depth.













MEMS

BIOMEMS

Results







Advanced sensitivity and excellent linearity ($R^2 \sim 0.99$)





Publication



Dóra Bereczki, András Füredi and Péter Fürjes "Plate Reader Compatible Microfluidic Chambers for Fluorescent Spectroscopy," Mátrafüred – International Meeting on Chemical Sensors, June 12-17, 2022, Visegrád, Hungary

Subjects

Semiconductor technology (Horváth Zsolt József)

Semiconductor devices (Horváth Zsolt József)



References

MEMS BIOMEMS

- (I) WHO Cancer Today- https://gco.iarc.fr/today/
- (2) W. E. Evans, M.V. Relling, J. H. Rodman, W. R. Crom, J. M. Boyett, and C.-H. Pui, "Conventional Compared with Individualized Chemotherapy for Childhood Acute Lymphoblastic Leukemia," *New England Journal of Medicine*, vol. 338, 1998, doi: 10.1056/NEJM199802193380803.
- (3) R. Fety et al., "Clinical impact of pharmacokinetically-guided dose adaptation of 5-fluorouracil: results from a multicentric randomized trial in patients with locally advanced head and neck carcinomas," Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, vol. 4, no. 9, Art. no. 9, Sep. 1998.
- (4) E. Gamelin et al., "Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer," *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*, vol. 26, no. 13, Art. no. 13, May 2008, doi: 10.1200/JCO.2007.13.3934 10.1016/j.clinbiochem.2016.05.001.
- (6) N. S. H. Motlagh, P. Parvin, F. Ghasemi, and F. Atyabi, "Fluorescence properties of several chemotherapy drugs: doxorubicin, paclitaxel and bleomycin," *Biomedical Optics Express*, vol. 7, no. 6, Art. no. 6, May 2016, doi: 10.1364/BOE.7.002400.
- (7) J.V. McGowan, R. Chung, A. Maulik, I. Piotrowska, J. M. Walker, and D. M. Yellon, "Anthracycline Chemotherapy and Cardiotoxicity," *Cardiovascular Drugs and Therapy*, vol. 31, no. 1, Art. no. 1, 2017, doi: 10.1007/s10557-016-6711-0



